Related Experiment Video

Updated: Aug 16, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.8K

MST4: A Potential Oncogene and Therapeutic Target in Breast Cancer

Ritu Arora1, Jin-Hwan Kim1,2, Ayechew A Getu3,4

  • 1Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.

Cells
|December 23, 2022
PubMed

Insights

Mammalian STE 20-like protein kinase 4 (MST4) drives breast cancer growth, migration, and invasion by promoting epithelial-mesenchymal transition (EMT). Targeting MST4 may offer a new therapeutic strategy for breast cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Mammalian STE 20-like protein kinase 4 (MST4) is upregulated in various cancers.
  • The specific role of MST4 in breast cancer and its involvement in epithelial-mesenchymal transition (EMT) remain largely unknown.

Purpose of the Study:

  • To investigate the function and clinical significance of MST4 in breast cancer.
  • To elucidate the molecular mechanisms by which MST4 influences breast cancer progression, including EMT.

Main Methods:

  • Overexpression and inhibition of MST4 in breast cancer cell lines.
  • Analysis of downstream signaling pathways, including Akt, E-cadherin, N-cadherin, Snail, and Slug.
  • Evaluation of MST4 expression in patient tissue microarrays and correlation with clinical data.

Main Results:

  • MST4 overexpression enhanced breast cancer cell growth, migration, and invasion.
  • MST4 inhibition significantly reduced these aggressive phenotypes.
  • MST4 was found to promote EMT by activating the Akt pathway and influencing key EMT markers.
  • Elevated MST4 expression in tumor tissues correlated with advanced cancer stage, lymph node metastasis, and poorer survival rates.

Conclusions:

  • MST4 exhibits oncogenic properties in breast cancer, contributing to proliferation, invasion, survival, and EMT.
  • MST4 represents a potential novel therapeutic target for breast cancer treatment.
Keywords:
AKTEMTMST4apoptosisbreast cancer

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K